Genus PLC
LSE:GNS

Watchlist Manager
Genus PLC Logo
Genus PLC
LSE:GNS
Watchlist
Price: 1 512 GBX -0.13%
Market Cap: 998.4m GBX
Have any thoughts about
Genus PLC?
Write Note

Genus PLC
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Genus PLC
Cash from Financing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
Genus PLC
LSE:GNS
Cash from Financing Activities
-ÂŁ2.8m
CAGR 3-Years
42%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Cash from Financing Activities
$21.1m
CAGR 3-Years
149%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Exscientia PLC
NASDAQ:EXAI
Cash from Financing Activities
-ÂŁ3.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Autolus Therapeutics PLC
NASDAQ:AUTL
Cash from Financing Activities
-$883k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bicycle Therapeutics PLC
NASDAQ:BCYC
Cash from Financing Activities
$519.9m
CAGR 3-Years
58%
CAGR 5-Years
44%
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
Cash from Financing Activities
ÂŁ34.3m
CAGR 3-Years
-33%
CAGR 5-Years
221%
CAGR 10-Years
N/A
No Stocks Found

Genus PLC
Glance View

Market Cap
998.4m GBX
Industry
Biotechnology

Amidst the rolling countryside of Britain, Genus PLC has quietly but profoundly reshaped the agricultural landscape since its formation. With roots tracing back to the British government's Milk Marketing Board, Genus blossomed into an influential player at the intersection of biotechnology and farming. This was not by chance, but through a strategic evolution into a global pioneer in animal genetics. At the heart of their operations, Genus enhances animal breeding by leveraging cutting-edge science, particularly the technology of selective breeding and genetics. They focus primarily on two types of livestock: bovine (cattle) and porcine (pigs), catering to agricultural sectors worldwide. Essentially, through their subsidiaries—ABS Global, focusing on cattle, and PIC, specializing in pigs—the company maximizes genetic improvements, aiding farmers in producing leaner, more disease-resistant, and ultimately more productive livestock. The business model of Genus PLC revolves around the intricate science of animal genetics and the commercial viability it crafts from this foundation. By developing genetically superior livestock, they provide a distinct competitive advantage to farmers who seek more yield with less resource input. The company harnesses sophisticated techniques like genomics and advanced biotechnologies, including gene editing, to achieve these outcomes. With each genetic line licensed, Genus receives a license fee, ensuring a steady stream of revenue. Additionally, sales channels are bolstered by continuous consultative partnerships with farmers to enhance productivity, cementing a cycle of value that perpetuates mutual growth. By marrying science with agricultural prosperity, Genus PLC remains a vanguard in a field where innovation is as essential as the soil itself.

GNS Intrinsic Value
1 945.64 GBX
Undervaluation 22%
Intrinsic Value
Price

See Also

What is Genus PLC's Cash from Financing Activities?
Cash from Financing Activities
-2.8m GBP

Based on the financial report for Jun 30, 2024, Genus PLC's Cash from Financing Activities amounts to -2.8m GBP.

What is Genus PLC's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 3Y
42%

Over the last year, the Cash from Financing Activities growth was 85%. The average annual Cash from Financing Activities growth rates for Genus PLC have been 42% over the past three years .

Back to Top